Trials / Unknown
UnknownNCT02712203
MMR and MMRV Vaccines: Effect of Age at First Dose on Safety and Immunogenicity of the Measles Component.
Measles-mumps-rubella and Measles-mumps-rubella-varicella Vaccines: Effect of Age at First Dose on Safety and Immunogenicity of the Measles Component.
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 5,808 (actual)
- Sponsor
- CHU de Quebec-Universite Laval · Academic / Other
- Sex
- All
- Age
- 11 Months – 22 Months
- Healthy volunteers
- Accepted
Summary
Healthy children who received two doses of GlaxoSmithKline (GSK) Biologicals' live attenuated measles-mumps-rubella vaccine (MMR) or measles-mumps-rubella-varicella vaccine (MMRV) in their second year of life.The purpose of this study is to assess the effect of the age at administration of the first dose on the reactogenicity and immunogenicity of the measles component of these vaccines. In addition, this study will evaluate if the effect of the age at first dose is modified by the type of vaccine administered.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MMR vaccine / MMRV vaccine | Subcutaneous injection, two doses |
Timeline
- Start date
- 2004-07-01
- Primary completion
- 2010-07-01
- Completion
- 2016-12-01
- First posted
- 2016-03-18
- Last updated
- 2016-03-18
Source: ClinicalTrials.gov record NCT02712203. Inclusion in this directory is not an endorsement.